Once powerful AI models are released, it’s nearly impossible to keep them from being misused. Minimizing the risk means ...
Is IDYA a good stock to buy? We came across a bullish thesis on IDEAYA Biosciences, Inc. on Valueinvestorsclub.com by ...
Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, ...
ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") , a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight ...
The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel Prize–winning technology is being adapted to fight cancer, with mRNA vaccines in ...
The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel-prize–winning technology is being adapted to fight cancer, with mRNA vaccines in ...
EXPLAIN ALL THIS. MINDY, WE’VE BEEN HEARING A LOT ABOUT THESE VACCINES OVER THE PAST FIVE, SIX YEARS, RIGHT? KAI RNA VACCINES GAINED A LOT OF ATTENTION DURING THE HEIGHT OF THE COVID 19 PANDEMIC. THE ...
The modification of lipid nanoparticles with aromatic rings and disulfide bonds enhances mRNA vaccine delivery. Researchers at the University of Pennsylvania (PA, USA) have modified lipid ...
Scientists are making rapid progress toward a long-awaited goal that could help to reshape cancer care: mRNA cancer vaccines with the potential to significantly boost the immune system’s ability to ...
Nonsense-mediated mRNA decay (NMD) is one of the most important processes in our cells to ensure that no faulty or incomplete proteins are produced. Scientists have now identified a central mechanism ...
A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...
Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results